We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+4.55%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$3.29B
AUM Growth
+$383M
Cap. Flow
+$337M
Cap. Flow %
10.23%
Top 10 Hldgs %
35.01%
Holding
141
New
13
Increased
43
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$38.1M
2
TMX
Terminix Global Holdings, Inc.
TMX
+$35.9M
3
EXAS
Exact Sciences
EXAS
+$35.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$33.8M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$27.1M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$34.5M
2
ALTR
Altair Engineering Inc
ALTR
+$23.1M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$22.9M
4
OPLN
Openlane
OPLN
+$21.6M
5
QURE icon
uniQure
QURE
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 47.89%
2 Technology 19.59%
3 Industrials 8.32%
4 Consumer Discretionary 7.68%
5 Communication Services 3.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOV
26
DELISTED
Myovant Sciences Ltd.
MYOV
$38.8M 1.18%
4,285,612
+1,816,591
+74% +$27.1M
XIFR
27
XPLR Infrastructure LP
XIFR
$1.12B
$38.7M 1.18%
802,200
+13,700
+2% +$635K
TMX
28
DELISTED
Terminix Global Holdings, Inc.
TMX
$36.4M 1.11%
+698,000
New +$35.9M
BHVN
29
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$36M 1.1%
823,000
+330,000
+67% +$18.6M
ASML icon
30
ASML
ASML
$626B
$36M 1.09%
173,000
– –
KALV
31
DELISTED
KalVista Pharmaceuticals
KALV
$33.2M 1.01%
1,500,000
+600,000
+67% +$14.1M
PAYC icon
32
Paycom
PAYC
$7.64B
$32M 0.97%
141,000
– –
COLL icon
33
Collegium Pharmaceutical
COLL
$1.15B
$31.9M 0.97%
2,427,976
+220,366
+10% +$2.95M
XPO icon
34
XPO
XPO
$23.5B
$31.2M 0.95%
1,561,353
-717,065
-31% -$14.6M
MYOK
35
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$31.1M 0.95%
621,000
+184,000
+42% +$8.96M
ANET icon
36
Arista Networks
ANET
$227B
$30.4M 0.92%
1,872,000
– –
GWPH
37
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$30.2M 0.92%
175,000
+81,994
+88% +$14.2M
NBIX icon
38
Neurocrine Biosciences
NBIX
$16.8B
$29.8M 0.91%
353,000
+83,000
+31% +$6.82M
MGA icon
39
Magna International
MGA
$18.7B
$29.2M 0.89%
587,000
-26,700
-4% -$1.32M
IDXX icon
40
Idexx Laboratories
IDXX
$44.1B
$28.3M 0.86%
+102,900
New +$25.4M
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
$28.1M 0.86%
535,000
+168,000
+46% +$9.65M
IPHI
42
DELISTED
INPHI CORPORATION
IPHI
$27.8M 0.85%
555,000
– –
TLND
43
DELISTED
Talend S.A. American Depositary Shares
TLND
$26.6M 0.81%
690,000
+301,967
+78% +$14.1M
VCYT icon
44
Veracyte
VCYT
$3.7B
$26.5M 0.81%
930,000
– –
CTAS icon
45
Cintas
CTAS
$81.9B
$26.3M 0.8%
444,000
– –
VRNS icon
46
Varonis Systems
VRNS
$4.59B
$26M 0.79%
1,260,000
– –
LEA icon
47
Lear
LEA
$6.54B
$25.6M 0.78%
184,000
– –
MRTX
48
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$25M 0.76%
+243,000
New +$18.9M
PEGI
49
DELISTED
Pattern Energy Group Inc. Class A
PEGI
$24.8M 0.75%
1,073,200
+43,200
+4% +$967K
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
$24.3M 0.74%
1,950,000
+335,000
+21% +$4.25M
1
2
3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Eventide Asset Management held 141 positions worth $3.29B, up 13% from $2.91B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Eventide Asset Management deployed $337M of net new capital in Q2 2019, opening 13 new positions and adding to 43 existing holdings. Its largest new stake was Terminix Global Holdings, Inc.: 698,000 shares worth $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 47% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was bluebird bio, an estimated $34.5M trimmed.

  • Eventide Asset Management's largest Q2 2019 buy was Terminix Global Holdings, Inc.: 698,000 shares worth $36.4M.
  • Eventide Asset Management added most to Zogenix, Inc. in Q2 2019, an estimated $38.1M increase.
  • Eventide Asset Management's biggest Q2 2019 reduction was bluebird bio, cutting an estimated $34.5M.
  • Eventide Asset Management fully exited Altair Engineering Inc in Q2 2019, selling an estimated $23.1M.
  • Eventide Asset Management's ten largest holdings make up 35% of its $3.29B portfolio in Q2 2019.
  • Eventide Asset Management opened 13 new positions and closed 25 in Q2 2019.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $3.29B.

Based on Eventide Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.